Prospective, randomized, and active controlled study of the efficacy of alginic acid and antacid in the treatment of patients with endoscopy-negative reflux disease

Table 1 Demographics between groups- (safety populations)

	All (134)	Topaal （-69）	Nacid （-65）	P
Sex
Male:Female	36:98	25:44	11:54	0.01861
Age (yr)	41.9  ±  13.4	41.6  ±  14.8	42.4  ±  11.8	0.73002
Body mass index(kg/m2)	23.1  ±  3.8	23.4  ±  3.8	22.8 ± 3.8	0.35472
Pulse rate (bpm)	75.2   ±  6.8	75.3  ±  7.0	75.1 ± 6.7	0.90752
SBP (mmHg)	117.0  ±  14.1	119.7  ±  14.2	114.1  ±  13.5	0.02112
DBP (mmHg)	75.0  ±  1.01	76.6  ±  9.5	73.2  ±  10.6	0.05162
History of heartburn (%)				0.96583
6–12 mo	75 (56.4)	39 (56.5)	36 (56.3)
1–5 yr	45 (33.8)	23 (33.3)	22 (34.4)
> 5 yr	13 (9.8)	7 (10.1)	6 (9.4)
Smoking (%)				0.40111
Yes	14 (10.5)	9 (13.0)	5 (7.7)
No	120 (89.5)	60 (87.0)	60 (92.3)
Drinking (%)				1.00001
Yes	5 (3.7)	3 (4.4)	2 (3.1)
No	129 (96.3)	66 (95.6)	63 (96.9)
Coffee (%)				0.08811
Yes	28 (20.9)	10 (14.5)	18 (27.7)
No	106 (79.1)	59 (85.5)	47 (72.3)
VAS (cm)				0.83882
Heartburn	7.5  ±  3.4	7.6  ±  3.0	7.4  ±  3.7
Regurgitation	8.2  ±  3.0	8.1  ±  3.1	8.2  ±  2.9
Dysphagia	1.7  ±  3.2	1.4  ±  3.0	2.0  ±  3.5
Epigastric pain	5.4  ±  4.1	4.6  ±  4.1	6.2  ±  3.9
Nausea	3.5  ±  3.8	3.3  ±  3.8	3.7  ±  3.8
Vomiting	1.1  ±  2.7	1.2  ±  2.7	1.0  ±  2.6
Belching	6.2  ±  4.0	5.9  ±  3.9	6.4  ±  4.1
Quality of life (%)				0.84893
Mild symptoms	4 (3.0)	3 (4.4)	1 (1.5)
Moderate w/o interfering	33 (24.6)	15 (21.7)	18 (27.7)
Moderate with interfering	66 (49.3)	36 (52.2)	30 (46.2)
Symptom as bad/worse	31 (23.1)	15 (21.7)	16 (24.6)

¹Fisher’s exact test; ²ANOVA model; ³Mantel–Henszel test; VAS: visual analog scale.